Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD
- To determine whether Wilms Tumor (WT) patients without WT1-associated congenital
anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to
progressive bilateral tumors, carry germline WT1 mutations.
- To determine whether non-syndromic WT1 germline mutation carriers have a substantially
higher incidence of ESRD than do WT patients who do not harbor WT1 mutations.
OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are
analyzed for WT1 mutations by gene sequencing and PCR.
Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations
Vicki Huff, PhD
M.D. Anderson Cancer Center
United States: Federal Government